Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
All content curated by
Published in Oncology

Journal Scan / Research · March 09, 2024

Efficacy and Safety of Tislelizumab Plus Gemcitabine and Cisplatin as a Postoperative Treatment for Patients With Muscle-Invasive Upper Tract Urothelial Carcinoma

BMC Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

BMC Cancer
The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma
BMC Cancer 2024 Feb 13;24(1)202, J Zhang, M Yang, D Wei, D Zhang, Z Chen, H Zhu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading